☆ 4.7 Article

Organ-specific heterogeneity in tumor-infiltrating immune cells and cancer antigen expression in primary and autologous metastatic lung adenocarcinoma

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma

Daniel J. Gross et al.

Summary: Analysis of tumor microenvironment in patients with stage II to III lung adenocarcinomas suggests that high PD-L1 expression on tumor associated macrophages or tumor cells is associated with improved survival from adjuvant chemotherapy (ACT), particularly when combined with high myeloid-lymphoid ratio or high stromal myeloid-derived suppressor cell ratio. Patients with low or no PD-L1 expression did not benefit from ACT treatment.

JOURNAL OF THORACIC ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer

Namrata S. Patil et al.

Summary: The study revealed that inhibitors of the PD-1/PD-L1 signaling axis have a significant overall survival benefit for non-small cell lung cancer (NSCLC) patients. Transcriptomic analysis and single-cell RNA sequencing showed that B and plasma cells play an important role in the efficacy of PD-L1 blockade in NSCLC.

CANCER CELL (2022)

添加到收藏夹

Editorial Material Oncology

Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors

Leonid Cherkassky et al.

Summary: The success of CAR T cell therapy in solid tumors is limited by insufficient tumor infiltration and T cell dysfunction. However, regional delivery of CAR T cells in solid tumor patients is safe and feasible, promoting tumor infiltration, proliferation, and trafficking, leading to persisting systemic immunity.

CANCER CELL (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial

Vivek Narayan et al.

Summary: CAR T cells show promising efficacy in hematologic malignancies, but face challenges in solid tumors due to the immunosuppressive tumor microenvironment. This study reports results from a phase 1 trial using engineered CAR T cells resistant to TGF-beta signaling in castration-resistant prostate cancer patients, showing both efficacy and dose-dependent toxicity. Future studies should explore multipronged approaches to improve outcomes in this setting.

NATURE MEDICINE (2022)

添加到收藏夹

Review Oncology

CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials

Navin K. Chintala et al.

Summary: Adoptive T-cell therapy, particularly represented by CAR T-cell therapy, aims to recognize cancer cell-surface antigens and lyse cancer cells. The success of CAR T-cell therapy in B-cell leukemia and lymphoma has led to efforts to expand this therapy to solid tumors.

LUNG CANCER (2021)

添加到收藏夹

Article Medicine, General & Internal

Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial

Enriqueta Felip et al.

Summary: IMpower010 study demonstrated a disease-free survival benefit with adjuvant atezolizumab versus best supportive care in patients who underwent complete resection followed by adjuvant chemotherapy, especially in the subgroup whose tumors expressed PD-L1 on 1% or more of tumor cells.

LANCET (2021)

添加到收藏夹

Article Oncology

Migration and invasion of NSCLC suppressed by the downregulation of Src/focal adhesion kinase using single, double and tetra domain anti-CEACAM6 antibodies

Shang-Jung Wu et al.

Summary: CEACAM6 is a cell adhesion receptor associated with tumor progression and metastasis in NSCLC. Anti-CEACAM6 antibodies with different valency were developed and expressed through protein engineering. These antibodies showed significant inhibition on NSCLC cell viability and invasion, suggesting therapeutic potential for NSCLC treatment.

TRANSLATIONAL ONCOLOGY (2021)

添加到收藏夹

Article Oncology

A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab

Prasad S. Adusumilli et al.

Summary: Regional delivery of mesothelin-targeted CAR T-cell therapy followed by pembrolizumab administration is safe, feasible, and demonstrates evidence of antitumor efficacy in patients with malignant pleural diseases. Our data support the investigation of combination immunotherapy with CAR T cells and PD-1 blockade agents in solid tumors.

CANCER DISCOVERY (2021)

添加到收藏夹

Article Oncology

Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression

Lucile Vanhersecke et al.

Summary: The presence of mature tertiary lymphoid structures is associated with improved response to immunotherapy in cancer patients, predicting objective response rates, progression-free survival, and overall survival. These findings support the potential use of TLS detection to select patients who are more likely to benefit from immune checkpoint blockade.

NATURE CANCER (2021)

添加到收藏夹

Article Oncology

Tuning the Antigen Density Requirement for CAR T-cell Activity

Robbie G. Majzner et al.

CANCER DISCOVERY (2020)

添加到收藏夹

Article Oncology

Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non -randomised, open -label, phase 2 trial

Sarah B. Goldberg et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Meeting Abstract Oncology

A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+recurrent high-grade serous ovarian cancer (HGSOC)

R. E. O'Cearbhaill et al.

GYNECOLOGIC ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Defining an Optimal Dual-Targeted CAR T-cell Therapy Approach Simultaneously Targeting BCMA and GPRC5D to Prevent BCMA Escape-Driven Relapse in Multiple Myeloma

Carlos Fernandez de Larrea et al.

BLOOD CANCER DISCOVERY (2020)

添加到收藏夹

Article Oncology

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Neal Ready et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer

Y. Kudo et al.

ANNALS OF ONCOLOGY (2019)

添加到收藏夹

Article Biotechnology & Applied Microbiology

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

Bryan D. Choi et al.

NATURE BIOTECHNOLOGY (2019)

添加到收藏夹

Article Oncology

Immune cell PD-L1 co-localizes with macrophages and is associated with outcome in PD-1 pathway blockade therapy

Yuting Liu et al.

CLINICAL CANCER RESEARCH (2019)

添加到收藏夹

Article Oncology

Differences in tumor microenvironments between primary lung tumors and brain metastases in lung cancer patients: therapeutic implications for immune checkpoint inhibitors

Ryul Kim et al.

BMC CANCER (2019)

添加到收藏夹

Review Immunology

Driving CARs on the uneven road of antigen heterogeneity in solid tumors

Nan Chen et al.

CURRENT OPINION IN IMMUNOLOGY (2018)

添加到收藏夹

Article Oncology

BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis

Peter R. Bucciarelli et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Review Oncology

Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies

Stefan Kiesgen et al.

JOURNAL OF THORACIC ONCOLOGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia

Jae H. Park et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Article Multidisciplinary Sciences

A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers

S. N. Gettinger et al.

NATURE COMMUNICATIONS (2018)

添加到收藏夹

Article Oncology

Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1

Takashi Eguchi et al.

ONCOTARGET (2017)

添加到收藏夹

Review Oncology

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

Aurore Morello et al.

CANCER DISCOVERY (2016)

添加到收藏夹

Article Oncology

Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer

A. S. Mansfield et al.

ANNALS OF ONCOLOGY (2016)

添加到收藏夹

Article Medicine, Research & Experimental

Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition

Leonid Cherkassky et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

添加到收藏夹

Article Medicine, Research & Experimental

Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Publication with Expression of Concern. See vol. 129, pg. 3464, 2019)

Meenakshi Hegde et al.

JOURNAL OF CLINICAL INVESTIGATION (2016)

添加到收藏夹

Article Oncology

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Tumor-Infiltrating CD10+ Neutrophil/CD20+ Lymphocyte Ratio as an Independent Prognostic Factor

Kyuichi Kadota et al.

JOURNAL OF THORACIC ONCOLOGY (2015)

添加到收藏夹

Article Oncology

The IASLC Lung Cancer Staging Project Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

Ramon Rami-Porta et al.

JOURNAL OF THORACIC ONCOLOGY (2015)

添加到收藏夹

Article Medicine, General & Internal

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

H. Borghaei et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

添加到收藏夹

Article Immunology

Target Antigen Density Governs the Efficacy of Anti-CD20-CD28-CD3 ζ Chimeric Antigen Receptor-Modified Effector CD8+ T Cells

Keisuke Watanabe et al.

JOURNAL OF IMMUNOLOGY (2015)

添加到收藏夹

Article Oncology

An ecological measure of immune-cancer colocalization as a prognostic factor for breast cancer

Carlo C. Maley et al.

BREAST CANCER RESEARCH (2015)

添加到收藏夹

Article Oncology

Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma

Stefan S. Kachala et al.

CLINICAL CANCER RESEARCH (2014)

添加到收藏夹

Article Multidisciplinary Sciences

Comprehensive molecular profiling of lung adenocarcinoma

Eric A. Collisson et al.

NATURE (2014)

添加到收藏夹

Article Multidisciplinary Sciences

PD-1 blockade induces responses by inhibiting adaptive immune resistance

Paul C. Tumeh et al.

NATURE (2014)

添加到收藏夹

Article Cell Biology

Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity

Prasad S. Adusumilli et al.

SCIENCE TRANSLATIONAL MEDICINE (2014)

添加到收藏夹

Article Oncology

Clinical Impact of Immune Microenvironment in Stage I Lung Adenocarcinoma: Tumor Interleukin-12 Receptor β2 (IL-12Rβ2), IL-7R, and Stromal FoxP3/CD3 Ratio Are Independent Predictors of Recurrence

Kei Suzuki et al.

JOURNAL OF CLINICAL ONCOLOGY (2013)

添加到收藏夹

Article Oncology

Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients

Elliot L. Servais et al.

CLINICAL CANCER RESEARCH (2012)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.